Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Patients"Success Rate Increases to Record High in 2000: Malpractice Lawsuits
April 23, 2001
- Market Share of Generics Should Be Considered in Pricing of Long-listed Drugs: JMA
April 23, 2001
- LDP's Commission Lists 4 Points of Discussion for NHI Pricing Reform
April 23, 2001
- Mr MRto Enable Physicians to Easily Access Information: Mr Tanimura of So-net M3
April 23, 2001
- REGULATORY NEWS IN BRIEF
April 23, 2001
- MEDICAL DEVICE NEWS IN BRIEF
April 23, 2001
- Marketing of Half-strength Preparations of Digoxin Expected
April 23, 2001
- Quintiles to Double Its Sales in Japan in FY2001
April 16, 2001
- REGULATORY NEWS IN BRIEF -2-
April 16, 2001
- Immediate PMS of Mobic Undertaken by Nippon Boehringer Ingelheim, Daiichi
April 16, 2001
- Bungyo Rate Exceeds 40%for Two Consecutive Months
April 16, 2001
- Developing Anti-AIDS Vaccine to Be Given Top Priority: Merck Company Foundation
April 16, 2001
- Reform of Medical Education Proposed to Promote Patient-centered Healthcare
April 16, 2001
- BUSINESS NEWS IN BRIEF -2-
April 16, 2001
- JPA Starts DispensingError/Incidents Reporting System
April 16, 2001
- Takeda's MRs Supported by Highest Percentage of Physicians
April 16, 2001
- Preventive Effects of Simvastatin on Coronary Events Confirmed: Banyu Symposium
April 16, 2001
- BUSINESS NEWS IN BRIEF -1-
April 16, 2001
- British Gov't Invites Japanese Drug Companies to Invest in UK
April 16, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
April 16, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…